The short version
- Why people research itFat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- What the evidence isPhase 3 in China, developed by Sciwind.
- What to watchPersistent vomiting.
How Ecnoglutide works
This is the one compound in the cohort whose defining number is published, and it is not a receptor selectivity ratio — it is a signaling bias ratio, which is a different and much stranger thing.
In receptor assays, ecnoglutide induced cAMP with an EC50 of 0.018 nM and induced GLP-1 receptor internalization with an EC50 greater than 10 µM Guo 2023. Put those two numbers on the same scale: 0.018 nanomolar against more than 10 micromolar is a separation of more than 500,000-fold between the two things this receptor can be made to do. That is not a tweak.
- Injectable
Where to get Ecnoglutide
When a vetted partner does, the link and code go here.
Research on Ecnoglutide6 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Human clinical evidence
Phase 3 in China, developed by Sciwind.
The trials are Chinese-population, and that changes how the percentages read — lower baseline BMI and different body composition make direct comparison with Western obesity trials unreliable in both directions.
Correlative data
No Western approval and no independent real-world record. GI tolerability in the trials looks class-typical.
It does appear in the research-chemical market, which is worth naming: what is sold there is not the trial material.
How the mechanism reads
A GLP-1 analog engineered as a cAMP-biased agonist — it preferentially activates the cAMP signaling arm of the receptor while recruiting less β-arrestin.
MechanisticBiased agonism is the interesting idea here. β-arrestin recruitment drives receptor internalization and desensitization, so a cAMP-biased agent should keep the receptor available longer. Whether that translates into a clinically distinguishable advantage is still an open question across the whole GPCR field, not just this drug.
Mechanistic
Sources
- Guo W, et al. Discovery of ecnoglutide - a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog. Molecular Metabolism 2023 · PMID 37364710
- Zhu D, et al. Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. Nature Communications 2024 · PMID 39333121
- Ji L, et al. Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes and Endocrinology 2025 · PMID 40555243
- He Y, et al. Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Diabetes and Endocrinology 2025 · PMID 40854315
- Shirley M. Ecnoglutide: First Approvals. Drugs 2026 · PMID 42412371
- Li F, et al. Effect of a Novel GLP-1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants. Diabetes, Obesity and Metabolism 2026 · PMID 42310888
- He L, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Internal Medicine 2022 · PMID 35344001
- Stefanakis K, et al. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. Metabolism 2024 · PMID 39481534
- Sattar N, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes and Endocrinology 2021 · PMID 34425083
- Muller TD, et al. Anti-obesity drug discovery: advances and challenges. Nature Reviews Drug Discovery 2022 · PMID 34815532
Ecnoglutide safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Medullary thyroid carcinoma or MEN2 in the family.
- A history of pancreatitis.
- Type 1 diabetes, or insulin use that leaves low blood sugar unmanaged.
- Gastroparesis.
- Pregnancy, or planning one while appetite is suppressed.
What’s expected
- GI effects dominate the trial tolerability tables, mostly mild to moderate.
- Weight loss and better glucose control from a cAMP-biased GLP-1 signal.
- Appetite quietening with early fullness.
Watch for
- Persistent vomiting.
- Pain high in the abdomen that moves to the back.
- Hoarseness or a neck lump.
Labs that tell you it’s working
- HbA1c: the main efficacy marker in the China phase 3 trials.
- Lipase: the pancreatic safety check.
- Comprehensive Metabolic Panel: dehydration shows in sodium, creatinine and glucose.
- Insulin (Fasting): insulin sensitivity should improve with weight loss.
Long-acting cAMP-biased GLP-1 analog favoring cAMP over beta-arrestin signaling; approved in China, so trial safety data exist. PMID 39333121 PMID 40555243 PMID 42412371
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Ecnoglutide FAQ4 common questions
- Is Ecnoglutide approved for human use?
- No. Ecnoglutide is a research compound.
- What is Ecnoglutide researched for?
- Fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- Which labs show whether it's doing anything?
- HbA1c; Lipase; Comprehensive Metabolic Panel; Insulin: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Ecnoglutide: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



